Next-generation pediatric care:nanotechnology-based and AI-driven solutions for cardiovascular,respiratory,and gastrointestinal disorders  

作　　者：Waldenice de Alencar Morais Lima Jackson G.de Souza Fátima García-Villén Julia Lira Loureiro Fernanda Nervo Raffin Marcelo A.C.Fernandes Eliana B.Souto Patricia Severino Raquel de M.Barbosa 

机构地区：[1]Laboratory of Galenic Pharmacy,Department of Pharmacy,Federal University of Rio Grande Do Norte,Natal,59012-570,Brazil [2]InovAI Lab,nPITI/IMD,Federal University of Rio Grande Do Norte,Natal,RN,59078-970,Brazil [3]Department of Pharmacy and Pharmaceutical Technology,School of Pharmacy,University of Granada,Campus of Cartuja,18071,Granada,Spain [4]Department of Computer Engineering and Automation,Federal University of Rio Grande Do Norte,Natal,RN,59078-970,Brazil [5]Laboratory of Pharmaceutical Technology,Faculty of Pharmacy,University of Porto,Rua Jorge de Viterbo Ferreira,228,4050-313,Porto,Portugal [6]Industrial Biotechnology Program,University of Tiradentes(UNIT),Aracaju,Sergipe,49032-490,Brazil [7]Department of Pharmacy and Pharmaceutical Technology,School of Pharmacy,University of Seville,C/Professor García González,2,41012,Seville,Spain

出　　处：《World Journal of Pediatrics》2025年第1期8-28,共21页世界儿科杂志(英文版)

基　　金：funded by EMERGIA,Junta de Andalucía,and Universidad de Sevilla,Spain,under contract number USE 23922-W to Raquel de Melo Barbosa(RMB);Support was also provided by FCT—Fundação para a Ciência e a Tecnologia,I.P.,for projects UIDP/04378/2020 and UIDB/04378/2020 within the Research Unit on Applied Molecular Biosciences—UCIBIO;project LA/P/0140/2020 within the Associate Laboratory Institute for Health and Bioeconomy—i4HB to Eliana B.Souto(EBS).

摘　　要：Background Global pediatric healthcare reveals significant morbidity and mortality rates linked to respiratory,cardiac,and gastrointestinal disorders in children and newborns,mostly due to the complexity of therapeutic management in pediatrics and neonatology,owing to the lack of suitable dosage forms for these patients,often rendering them“therapeutic orphans”.The development and application of pediatric drug formulations encounter numerous challenges,including physiological heterogeneity within age groups,limited profitability for the pharmaceutical industry,and ethical and clinical constraints.Many drugs are used unlicensed or off-label,posing a high risk of toxicity and reduced efficacy.Despite these circumstances,some regulatory changes are being performed,thus thrusting research innovation in this field.Data sources Up-to-date peer-reviewed journal articles,books,government and institutional reports,data repositories and databases were used as main data sources.Results Among the main strategies proposed to address the current pediatric care situation,nanotechnology is specially promising for pediatric respiratory diseases since they offer a non-invasive,versatile,tunable,site-specific drug release.Tissue engineering is in the spotlight as strategy to address pediatric cardiac diseases,together with theragnostic systems.The integration of nanotechnology and theragnostic stands poised to refine and propel nanomedicine approaches,ushering in an era of innovative and personalized drug delivery for pediatric patients.Finally,the intersection of drug repurposing and artificial intelligence tools in pediatric healthcare holds great potential.This promises not only to enhance efficiency in drug development in general,but also in the pediatric field,hopefully boosting clinical trials for this population.Conclusions Despite the long road ahead,the deepening of nanotechnology,the evolution of tissue engineering,and the combination of traditional techniques with artificial intelligence are the most recently reporte

关 键 词：Artificial intelligence Conventional therapy NANOTECHNOLOGY PEDIATRICS Theragnostics 

分 类 号：R72[医药卫生—儿科]